Lillyโs Full Retatrutide Data Raises the Stakes in the Next Obesity Drug Race
Eli Lilly has released full phase 3 data on retatrutide, intensifying competition in the fast-growing obesity drug market and reinforcing investor focus on next-generation weight-loss therapies. The results add to a broader pipeline battle that is increasingly centered on efficacy, durability, and potential benefits beyond weight reduction.
